Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Spatial single cell analysis of tumor microenvironment remodeling pattern in primary central nervous system lymphoma. | Leukemia | 2023 | 37120690 | PubTator, text mining | PubMed |
| Inhibitory Potential of the Ocimum sanctum Phytochemicals on Bruton's Tyrosine Kinase, a Well-Known Drug Target for Treatment of Chronic Lymphocytic Leukemia: An In Silico Investigation. | Molecules | 2023 | 37110523 | PubTator, text mining | PubMed |
| The Wheel of p53 Helps to Drive the Immune System. | Int J Mol Sci | 2023 | 37108808 | PubTator, text mining | PubMed |
| Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies. | Int J Mol Sci | 2023 | 37108348 | PubTator, text mining | PubMed |
| Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma. | Commun Biol | 2023 | 37106027 | PubTator, text mining | PubMed |
| The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome. | Leukemia | 2023 | 37100882 | PubTator, text mining | PubMed |
| MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma. | J Cancer Res Clin Oncol | 2023 | 37093346 | PubTator, text mining | PubMed |
| IL-1β Is an Androgen-Responsive Target in Macrophages for Immunotherapy of Prostate Cancer. | Adv Sci (Weinh) | 2023 | 37092583 | PubTator, text mining | PubMed |
| ProgClust: A progressive clustering method to identify cell populations. | Front Genet | 2023 | 37091787 | PubTator, text mining | PubMed |
| Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors. | Brain Tumor Pathol | 2023 | 37086325 | PubTator, text mining | PubMed |
| Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting. | Exp Hematol Oncol | 2023 | 37085931 | PubTator, text mining | PubMed |
| Cancer-Associated Fibroblasts Are Key Determinants of Cancer Cell Invasion in the Earliest Stage of Colorectal Cancer. | Cell Mol Gastroenterol Hepatol | 2023 | 37085135 | PubTator, text mining | PubMed |
| The Polyamine-Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma. | Blood Cancer Discov | 2023 | 37070973 | PubTator, text mining | PubMed |
| Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. | Blood Adv | 2023 | 37067952 | PubTator, text mining | PubMed |
| A hybrid demultiplexing strategy that improves performance and robustness of cell hashing. | bioRxiv | 2023 | 37066221 | PubTator, text mining | PubMed |
| NF-kB and the CLL microenvironment. | Front Oncol | 2023 | 37064123 | PubTator, text mining | PubMed |
| Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. | Front Immunol | 2023 | 37063860 | PubTator, text mining | PubMed |
| Advances in the multi-omics landscape of follicular lymphoma. | Int J Biol Sci | 2023 | 37063433 | PubTator, text mining | PubMed |
| Bruton tyrosine kinase inhibitors for multiple sclerosis. | Nat Rev Neurol | 2023 | 37055617 | PubTator, text mining | PubMed |
| MYD88-Mutated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma as a Distinctive Molecular Subgroup Is Associated with Atypical Immunophenotypes in Chinese Patients. | J Clin Med | 2023 | 37048750 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=36